Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.55 |
| ▸ | KHK | P50053 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229711 | 0.87 | CFTR (0.52) | TNKSPARP1TNKS2KHK | |
| SCHEMBL5232141 | 0.85 | KDM4E (0.52) | TNKSPARP1TNKS2KDM4EMAPT | |
| SCHEMBL5235453 | 0.83 | PDE7A (0.48) | KHKKDM4EALDH1A1MAPT | |
| SCHEMBL5232557 | 0.82 | TNKS (0.52) | TNKSPARP1TNKS2KDM4EMAPT | |
| SCHEMBL5229885 | 0.81 | PDE5A (0.58) | KHKKDM4EALDH1A1 | |
| SCHEMBL5230207 | 0.80 | PDE7A (0.53) | TNKSPARP1TNKS2 | |
| SCHEMBL5228261 | 0.79 | TNKS (0.51) | TNKSPARP1TNKS2KDM4EALDH1A1 | |
| SCHEMBL5229820 | 0.79 | TNKS (0.51) | TNKSPARP1TNKS2KDM4EALDH1A1 | |
| SCHEMBL5228258 | 0.79 | TNKS (0.51) | TNKSPARP1TNKS2KDM4EALDH1A1 | |
| SCHEMBL1814076 | 0.79 | PDE5A (0.41) | PARP1KHKKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1454897-B1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY | ASUBIO PHARMA CO LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | OMEROS CORPORATION | 2005-07-07 | — | — | US | disclosed |
| EP-1454897-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | PDE7B, PDE3B, PDE3A | TNKS 1602/4885PARP1 3442/4885TNKS2 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.